Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 57
Confirmed by 4 outlets

FDA clears GSK lung cancer drug for advanced cases

The FDA granted accelerated approval Tuesday to a GSK drug for patients with an advanced form of lung cancer, Reuters reported. The clearance targets patients whose disease progressed after earlier treatments, a group with limited options left.

By the Paparazzi desk November 17, 2026 · 9:38 AM · Sources: 4 outlets · 0 views
Fact boxTrust 74/100 · Developing
What we verified
  • 4 sources report it: yahoo.com, msn.com, oncnursingnews.com, breakingthenews.net.
  • The source published it on Nov 17, 2026 at 9:38 AM.
What we couldn't

Nothing open. Every check passed.

The US Food and Drug Administration handed GSK's lung cancer drug an accelerated approval on Tuesday, Reuters reported. The green light covers patients with an advanced form of the disease, not the general lung cancer population.

The approval is aimed at patients whose disease has already progressed after earlier treatments — a group with few remaining options. GSK, formally GlaxoSmithKline, now has a cleared path to market the therapy in that setting.

Sponsored

The company has not yet disclosed pricing or a rollout date. Reuters' report was filed from Bengaluru by Kamal Choudhury, with Shailesh Kuber editing.

TopicsGSK · FDA · GlaxoSmithKline

Share

Written by AI from verified reporting.

More stories

  • Health & science 33 minutes ago · curetoday.com · 0 views
    FDA Fast-Tracks Nelkarmi for Lung Cancers That Outsmarted Earlier Drugs
  • Health & science 50 minutes ago · techtimes.com · 0 views
    Pierre Fabre's lung cancer pill wins FDA fast track with no data public
  • Health & science 2 hours ago · apnews.com · 0 views
    US and Mexico stripped of measles-free status, international health officials say
  • Health & science 3 hours ago · cbsnews.com · 0 views
    China fires scientist after girl, 6, died in hidden gene-editing trial
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.